Asian macaques infected with simian immunodeficiency viruses (SIVs) isolated from African non-human primates develop a disease similar to human AIDS. SIV enters its target cells by binding to CD4 and a coreceptor, typically CCR5. Maraviroc is an entry inhibitor of human immunodeficiency virus type 1 (HIV-1) that prevents the interaction between CCR5 and the surface subunit gp120 of the viral envelope glycoprotein (Env). Thus far, the activity of maraviroc on SIV entry has been poorly studied. Here, we determined in vitro pharmacological parameters of the effect of maraviroc on the SIV Env association with CCR5. Cell-to-cell fusion inhibition assays were used to compare the susceptibility to maraviroc of the SIVsmmPBj Env-CCR5 interaction wi...
AbstractHuman immunodeficiency virus type 1 (HIV-1) resistance to CCR5 antagonists, including maravi...
Sexually transmitted HIV-1 strains utilize the chemokine receptor CCR5 for viral entry and inhibitor...
Maraviroc (MVC) is an allosteric inhibitor of human immunodeficiency virus type 1 (HIV-1) entry, and...
Shawna M Woollard, Georgette D Kanmogne Department of Pharmacology and Experimental Neuroscience, U...
AbstractHuman immunodeficiency virus type 1 (HIV-1) fusion with its target cells is initiated by seq...
Abstract: While a successful HIV vaccine will likely take several more years to become a reality, ma...
Maraviroc (MVC) inhibits the entry of human immunodeficiency virus type 1 (HIV-1) by binding to and ...
Maraviroc (MVC) inhibits the entry of human immunodeficiency virus type 1 (HIV-1) by binding to and ...
Human and simian immunodeficiency viruses (HIV and SIV) enter target cells using CD4, the primary ce...
BACKGROUND: Maraviroc (MVC) and other CCR5 antagonists are HIV-1 entry inhibitors that bind to- and ...
Natural host sooty mangabeys infected with simian immunodeficiency viruses (SIV) exhibit high plasma...
Natural host sooty mangabeys infected with simian immunodeficiency viruses (SIV) exhibit high plasma...
Background: The CCR5 antagonist maraviroc (MVC) inhibits human immunodeficiency virus type 1 (HIV-1)...
HIV-1 replication and thus, the progression of infected individuals to AIDS can now be largely contr...
Human immunodeficiency virus (HIV) infection of host cells begins with binding of viral envelope (En...
AbstractHuman immunodeficiency virus type 1 (HIV-1) resistance to CCR5 antagonists, including maravi...
Sexually transmitted HIV-1 strains utilize the chemokine receptor CCR5 for viral entry and inhibitor...
Maraviroc (MVC) is an allosteric inhibitor of human immunodeficiency virus type 1 (HIV-1) entry, and...
Shawna M Woollard, Georgette D Kanmogne Department of Pharmacology and Experimental Neuroscience, U...
AbstractHuman immunodeficiency virus type 1 (HIV-1) fusion with its target cells is initiated by seq...
Abstract: While a successful HIV vaccine will likely take several more years to become a reality, ma...
Maraviroc (MVC) inhibits the entry of human immunodeficiency virus type 1 (HIV-1) by binding to and ...
Maraviroc (MVC) inhibits the entry of human immunodeficiency virus type 1 (HIV-1) by binding to and ...
Human and simian immunodeficiency viruses (HIV and SIV) enter target cells using CD4, the primary ce...
BACKGROUND: Maraviroc (MVC) and other CCR5 antagonists are HIV-1 entry inhibitors that bind to- and ...
Natural host sooty mangabeys infected with simian immunodeficiency viruses (SIV) exhibit high plasma...
Natural host sooty mangabeys infected with simian immunodeficiency viruses (SIV) exhibit high plasma...
Background: The CCR5 antagonist maraviroc (MVC) inhibits human immunodeficiency virus type 1 (HIV-1)...
HIV-1 replication and thus, the progression of infected individuals to AIDS can now be largely contr...
Human immunodeficiency virus (HIV) infection of host cells begins with binding of viral envelope (En...
AbstractHuman immunodeficiency virus type 1 (HIV-1) resistance to CCR5 antagonists, including maravi...
Sexually transmitted HIV-1 strains utilize the chemokine receptor CCR5 for viral entry and inhibitor...
Maraviroc (MVC) is an allosteric inhibitor of human immunodeficiency virus type 1 (HIV-1) entry, and...